Twist Bioscience (NASDAQ:TWST) CEO Emily Leproust Sells 4,573 Shares of Company Stock

Twist Bioscience Corporation (NASDAQ:TWST) CEO Emily Leproust sold 4,573 shares of Twist Bioscience stock in a transaction that occurred on Tuesday, November 3rd. The shares were sold at an average price of $135.40, for a total value of $619,184.20. Following the completion of the transaction, the chief executive officer owned 558,187 shares of the company’s stock, valued at approximately $75,578,519.80. The trade was a 0.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Twist Bioscience Stock Down 15.4%

NASDAQ:TWST opened at $120.61 on Friday. The firm has a market capitalization of $7.56 billion, a PE ratio of -54.33 and a beta of 2.25. The stock has a 50 day moving average of $152.00 and a 200-day moving average of $90.68. Twist Bioscience Corporation has a 52 week low of $23.30 and a 52 week high of $219.71. The company has a current ratio of 2.67, a quick ratio of 2.38 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%. The company had revenue of $118.38 million for the quarter, compared to analyst estimates of $114.55 million. During the same quarter in the previous year, the company posted $0.33 earnings per share. The firm’s revenue for the quarter was up 23.2% compared to the same quarter last year. Analysts predict that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Trending Headlines about Twist Bioscience

Here are the key news stories impacting Twist Bioscience this week:

• Positive Sentiment: Twist Bioscience has launched MRD Express, a development that could support its presence in the minimal residual disease testing market. The article also notes the stock is entering earnings week, when investors may look for updates on the product and business outlook. Read More.
• Neutral Sentiment: A separate analysis describes an “undervalued” investment narrative but flags the company’s sales valuation as expensive, presenting a mixed view rather than a clear near-term catalyst. Read More.
• Neutral Sentiment: Four executives and insiders, including CEO Emily M. Leproust, sold a combined 6,677 shares at $135.40. The transactions were reported as covering tax withholding obligations related to equity-award vesting, which makes them less indicative of discretionary selling.
• Negative Sentiment: Shares fell amid a negative report from The Bear Cave/Hunterbrook. The available headline does not detail the report’s claims, but the coverage appears to have weighed on investor sentiment. Read More.

Hedge Funds Weigh In On Twist Bioscience

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Lisanti Capital Growth LLC bought a new position in Twist Bioscience during the third quarter valued at about $5,584,000. Ritholtz Wealth Management acquired a new position in Twist Bioscience during the third quarter worth about $327,000. Lido Advisors LLC acquired a new position in Twist Bioscience during the third quarter worth about $8,162,000. Fulcrum Asset Management LLP bought a new stake in Twist Bioscience in the third quarter worth about $8,668,000. Finally, Brighton Jones LLC bought a new stake in Twist Bioscience in the third quarter worth about $231,000.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on TWST shares. Barclays raised their target price on Twist Bioscience from $112.00 to $215.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. BWS Financial restated a “sell” rating and set a $45.00 price target on shares of Twist Bioscience in a research report on Friday, September 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a report on Monday, September 21st. Piper Sandler increased their price objective on shares of Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a report on Wednesday, August 5th. Finally, Canaccord Genuity Group lifted their price objective on shares of Twist Bioscience from $120.00 to $205.00 and gave the company a “buy” rating in a research report on Monday, October 12th. Seven equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $153.00.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA and related products for life sciences research. The company uses a proprietary silicon-based platform to produce high-quality DNA at scale, supporting applications in synthetic biology, drug discovery and development, agriculture, and academic and industrial research.

Its offerings include synthetic genes, oligonucleotides, gene fragments, variant libraries, and antibody discovery products.